Cannlabs Inc. · OTC:CANL
Cannlabs — Investor Presentation (December 2014)
11 slides from Cannlabs's investor presentation, Dec 15, 2014
Slide 1: OTCQB: CANL
OTCQB: CANL
Slide 2: Overview and Trading Statistics
© CannLabs, Inc. – All rights reserved | 2 Overview Trading Statistics Price (as of 12/12/14) $0.92 Volume (3 month) 13,351 52 Week High/Low $2.43 /$0.85 Total Shares Outstanding 65.5M Float 13.9M % Insiders 79% Market Cap $56 M Other Headquarters Denver, CO Public Since June 12, 2014 Website www.ca
Slide 3: Who Are We?
© CannLabs, Inc. – All rights reserved | 3 Who Are W e? • CannLabs, Inc., is a respected authority and advisor to commercial, governmental and educational entities focused on the Cannabis industry. The company leverages its testing processes, propriety scientific, cloud - based business intelligence
Slide 4: Who Are We?
© CannLabs, Inc. – All rights reserved | 4 Who Are We? • One of the pioneers and leaders • Four years running • One of the first licensed in CO, CT and NV • Multi - State Platform • Health and safety checkpoint in the seed to sale supply chain • Technology • Dedicated to maintaining the highest stan
Slide 5: Industry Dynamics
© CannLabs, Inc. – All rights reserved | 5 Industry Dynamics • It’s a National Issue with increased consumer education leading to voter support • Currently there are 23 states approved for medical marijuana + D.C., and 4 states for recreation with 10 more currently in legislation • The medical and a
Slide 6: Market Opportunity
© CannLabs, Inc. – All rights reserved | 6 Market Opportunity • Market expected to be $2.5 billion in 2014 with a 35% CAGR through 2018 ( CannaBuisnees Media: 2014) • Retail marijuana sales revenues could reach ~ $35 billion/year by 2020, if full legalization occurs in all 50 States and D.C. ( Green
Slide 7: Cannabis Health & Safety
© CannLabs, Inc. – All rights reserved | 7 Cannabis Health & Safety • Potential for growers to inadvertently introduce unsafe cannabis products to consumers • Rapidly growing industry with expanding regulatory mandates: American Herbal Pharmacopoeia® (AHP) guidelines • Potency testing • Foreign mate
Slide 8: Our Business Model
© CannLabs, Inc. – All rights reserved | 8 Our Business Model • Immediate revenue growth achieved through testing • Lead generator into other higher margin revenue streams including consulting and product re - formulation • Large portfolio of test results (4 Years of data collected from 1000’s of te
Slide 9: Revenue & Growth Opportunity Drivers
© CannLabs, Inc. – All rights reserved | 9 Revenue & Growth Opportunity Drivers $ Revenue $ Sustained Growth Opportunities Current Mandated Testing (Potency, residual solvents, heavy metals, Aflatoxin , etc.) Advanced Testing (Food safety quality, genetics, control contamination, shelf life and stor
Slide 10: National Footprint
© CannLabs, Inc. – All rights reserved | 10 National Footprint • Colorado 4000 sq. ft. • Licences:496 Medical, 242 Recreational • Companies:225 (112 CANL) 49% share • Connecticut 4000 sq. ft. • 4 Commercial Licensed Growers • 2 Contracted with CANL 50% Share • Adheres to American Herbal Pharmacopoei
Slide 11: Investment Highlights
© CannLabs, Inc. – All rights reserved | 11 Investment Highlights • Sector and market are in infancy, exponential growth is anticipated (~$2.5B market estimated in 2014, growing at 35% CAGR) • Testing and services are needed and required ongoing • Health and safety checkpoint in the seed to sale sup